Design and Synthesis of PA_N Endonuclease Inhibitors through Spirocyclization Strategy against Influenza A Virus

The PAN endonuclease inhibitor baloxavir marked a significant advancement in influenza treatment. Herein, we reported the development of PAN inhibitors through structural simplification of baloxavir̀s tricyclic system coupled with strategic incorporation of a spirocyclic architecture, which aims to construct a new metal-binding pharmacophore with distinct three-dimensional features. Lead 39-(S) was identified and exhibited nanomolar potency against influenza virus polymerase complexes (IC50 = 17.4 nM), which was mechanistically attributed to PAN endonuclease inhibition. Furthermore, 39-(S) demonstrated robust antiviral activities against multiple current and different influenza virus strains while showing minimal cytotoxicity in MDCK cells, ensuring an exceptional selectivity index of more than 2.4 × 105 during antiviral treatment. Additionally, both 39-(S) and its prodrug 41 significantly suppressed viral replication in an A/WSN/33 infected mouse model with efficacy profiles remarkably comparable to those of baloxavir. Collectively, 39-(S) emerges as a potent PAN inhibitor with the potential for further development.